CleverHealth Network, established in 2017, is a health technology ecosystem in which companies and health care experts develop better treatment solutions for Finns and successful export products for companies. Product and service innovations are based on HUS’s extensive health data and the leading expertise of clinicians.
The participants of the ecosystem, coordinated by HUS and funded by Business Finland, include AstraZeneca, BCB Medical, BC Platforms, CGI, Fujitsu, GE Healthcare, Hewlett Packard Enterprise, Innofactor, Medtronic, Microsoft, Novartis, Pfizer, Planmeca, Productivity Leap, Roche, Siemens Healthineers, Takeda, Telia, Tietoevry, Varian.
CleverHealth Network’s vision is to be an internationally renowned ecosystem, which processes and cultivates health and welfare data, a forerunner in the health care revolution, and to create dozens of world-class solutions related to the cultivation of healthcare data.
The health of the citizens always comes first.
We dare to dream the future
- We improve health
We develop technological solutions based on health and welfare data that provide even better and more precise patient care. - We develop treatments together
We bring together health technology competence, HUS’s world-class professionals and researchers, and high-quality health data. - We remodel the entire health care business
We change and enhance the practices in health care. - We take Finland to the cutting edge of health technology
We build new successful exports, help SMEs access the international market, and bring foreign investments to Finland.
Operating model
The innovation functions will take place in the development projects to be established within the ecosystem, combining interdisciplinary talent with agile joint development models.
An essential part of the ecosystem is the HUS data lake, an analysis and storage location for large masses of data built by HUS with the support of the Finnish Innovation Fund Sitra. HUS data lake is internationally unique in its extent and high-quality.
Leveraging data will facilitate improved treatment planning, more accurate diagnostics as well as proactive and more personalized treatment.